KIR3DL2 and primary cutaneous T-cell non-Hodgkin lymphoma: The restricted expression of KIR3DL2 in normal immune cells, and the possibility to selectively target the tumor cells in CTCL, led to the development of a humanized mAb for an effective treatment strategy.